| Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC FC Santini, H Rizvi, AJ Plodkowski, A Ni, ME Lacouture, ... Cancer immunology research 6 (9), 1093-1099, 2018 | 290 | 2018 |
| Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) ACZ Gelatti, A Drilon, FC Santini Lung cancer 137, 113-122, 2019 | 186 | 2019 |
| Endocrine side effects of cancer immunotherapy P Cukier, FC Santini, M Scaranti, AO Hoff Endocrine-related cancer 24 (12), T331-T347, 2017 | 178 | 2017 |
| PD-1/PD-L1 axis in lung cancer FC Santini, MD Hellmann The Cancer Journal 24 (1), 15-19, 2018 | 70 | 2018 |
| Atezolizumab for the treatment of non-small cell lung cancer FC Santini, CM Rudin Expert review of clinical pharmacology 10 (9), 935-945, 2017 | 56 | 2017 |
| Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD (L)-1 therapy. FC Santini, H Rizvi, O Wilkins, M van Voorthuysen, E Panora, D Halpenny, ... Journal of Clinical Oncology 35 (15_suppl), 9012-9012, 2017 | 53 | 2017 |
| The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers JK Sabari, FC Santini, AM Schram, I Bergagnini, R Chen, C Mrad, WV Lai, ... OncoTargets and therapy, 1983-1992, 2017 | 53 | 2017 |
| Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer JE Chaft, I Dagogo-Jack, FC Santini, J Eng, BY Yeap, B Izar, E Chin, ... Lung Cancer 122, 67-71, 2018 | 44 | 2018 |
| Changing the therapeutic landscape in non-small cell lung cancers: the evolution of comprehensive molecular profiling improves access to therapy JK Sabari, F Santini, I Bergagnini, WV Lai, KC Arbour, A Drilon Current oncology reports 19, 1-8, 2017 | 44 | 2017 |
| Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer BJ Solomon, CC Zhou, A Drilon, K Park, J Wolf, Y Elamin, HM Davis, ... Future Oncology 17 (7), 763-773, 2021 | 38 | 2021 |
| Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res 2018; 6: 1093–9. doi: 10.1158/2326-6066 FC Santini, H Rizvi, AJ Plodkowski, A Ni, ME Lacouture, ... CIR-17-0755.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 37 | |
| First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC C Zhou, B Solomon, HH Loong, K Park, M Pérol, E Arriola, S Novello, ... New England Journal of Medicine 389 (20), 1839-1850, 2023 | 35 | 2023 |
| NTRK fusions in lung cancer: from biology to therapy G Harada, FC Santini, C Wilhelm, A Drilon Lung Cancer 161, 108-113, 2021 | 30 | 2021 |
| Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res. 2018; 6 (9): 1093–9 FC Santini, H Rizvi, AJ Plodkowski, A Ni, ME Lacouture, ... External Resources Crossref (DOI), 0 | 27 | |
| TRK inhibitors in non-small cell lung cancer G Harada, ABL Gongora, CM da Costa, FC Santini Current Treatment Options in Oncology 21, 1-12, 2020 | 19 | 2020 |
| Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung … R Thummalapalli, E Bernstein, B Herzberg, BT Li, A Iqbal, I Preeshagul, ... JCO Precision Oncology 7, e2300030, 2023 | 17 | 2023 |
| Identification of the TP53 p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome RL Sandoval, C Masotti, MP de Macedo, MFSA Ribeiro, ACR Leite, ... JCO Global Oncology 7, 1141-1150, 2021 | 11 | 2021 |
| Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: a Latin American perspective RA Athanazio, JM Ceresetto, LJ Marfil Rivera, G Cesarman-Maus, ... Clinical and Applied Thrombosis/Hemostasis 28, 10760296221082988, 2022 | 8 | 2022 |
| LBA4 Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC HHF Loong, K Goto, BJ Solomon, K Park, M Pérol, E Arriola, S Novello, ... Annals of Oncology 34, S1303, 2023 | 7 | 2023 |
| Combination MET-and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers? FC Santini, S Kunte, A Drilon Translational lung cancer research 6 (3), 393, 2017 | 6 | 2017 |
